including a low rate of conjunctivitis, which is a recognised side effect with Dupixent. The drug has also been approved in the EU, although it was turned down by the FDA in the US, where rights ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

They also point to lebrikizumab’s safety profile, including low rates of conjunctivitis, which is a known side effect of Dupixent. In trials, Ebglyss showed good and durable efficacy ...